by Exnihiloest » 01/03/20, 15:07
Regarding the price of Zolgesma.
In trade, it is always the buyer who makes the price. Except in the case of extremely rare philanthropy, the trader sets the price according to what the buyer is ready to pay, sometimes with a skillful balance to achieve in order to optimize his sales, between the number of potential buyers and the selling price.
In the present case the calculation is quite simple, given that the old competing drug was at $ 85000 per dose, which given the number of injections over 10 years of treatment, exceeds 2 million. A single injection of the new product would be more effective than treatment with the other over several years, so Novartis charges for the service.
Novartis uses the commercial practices that we find everywhere, including in the small trader, but since it is a question here of health, and the health of children, we find that lamentable. We are right but it is not used for much.
Why don't we have a powerful public research capable, when it obtains results, of obtaining cooperation with the private sector for manufacturing at controlled prices? Why should critical drugs not be produced publicly?
These are the kinds of questions one might ask and the answers could improve the system, but for which the trolls of this forum already have the answer "it is because the governments are linked with the pharmaceutical industry", move around, there is nothing to do, but bands of cracks to destroy! Here we are, we always know in advance what these trolls have to say, so childish and vindictive.
0 x